Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

REMS Standardization Could Help Opioid Education Efforts

Executive Summary

FDA hopes to begin accepting Risk Evaluation and Mitigation Strategy documents in structured product labeling format later this year.

Advertisement

Related Content

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
FDA REMS Platform Will Make Safety Plans Easy – Maybe Too Easy?
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
REMS Communications Need FDA Logo To Boost Doctors’ Attention, Advisors Say

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register